-- Scott Roberts
FRIDAY, Jan. 17, 2014 (HealthDay News) -- A new test to help
diagnose developmental delays and intellectual disability in
children based on genetic abnormalities has been approved by the
U.S. Food and Drug Administration.
The Affymetrix CytoScan DX Assay scans the entire genetic code
from a blood sample and detects chromosomal variations that can
lead to developmental and learning problems in children, the agency
said Friday in a news release.
Intellectual disability affects as many as 3 percent of children
in the United States, the agency said.
Analysis of 960 blood specimens found the new test was better at
detecting chromosomal abnormalities that could lead to intellectual
disability than other standard tests, the FDA said.
The new test is produced by Affymetrix Inc., based in Santa
Medline Plus has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.